Skip to Content

Publications

Xceleron and Lundbeck Publish on the Use of AMS to Meet the MIST Guidelines

Date Posted: March 9, 2012

Date Posted: 9th March, 2012 Summary: Title: Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach Authors: Graham Lappin, Mark Seymour, Gerhard Gross, Martin Jørgensen, Morten Kall & Lisbet Kværnø Bioanalysis; February 2012, Vol. 4, No. 4, Pages 407-416 , DOI 10.4155/bio.11.334 The metabolites in safety testing andContinue Reading

Read more >>

Single and Multiple-Dose IV and Oral Pharmacokinetics of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) During a Phase 1 Study in Healthy Female Subjects

Date Posted: January 31, 2012

Summary: This poster, published at the ASCPT meeting in Dallas, Texas, in 2011, describes how scientists at Genentech used the AMS enabled IV tracer approach to investigate the previously observed non-linear pharmacokinetics (PK) of vismodegib (GDC-0449). By administering a 14C-labelled IV microtracer of Vismodigib in addition to an oral dose, they were able to determineContinue Reading

Read more >>

Accelerator MS: It’s Role as a Frontline Bioanalytical Technique

Date Posted: December 23, 2011

Summary: A paper on a presentation by Dr Mark Seymour on the use of AMS as a frontline technique in bioanalytical detection has been published in the December 2011 issue of Bioanalysis. The paper was presented at the Reid Bioanalytical Forum in July earleir this year. The full paper can be downloaded from the FutureContinue Reading

Read more >>

Xceleron Publish Data on Quantitative Target Binding in vivo

Date Posted: November 28, 2011

Summary: Target Mediated Disposition of 14C-anti-CEA using Accelerator Mass Spectrometry It has been shown in a previous study using Iodine-125, that the plasma clearance of T84.66 (anticarcinoembryonic antigen, CEA) in a xenograft mouse model can be used to test for the presence of CEA-positive tumors. Transferring the technique into humans would be problematic because ofContinue Reading

Read more >>

AAPS Poster with AstraZeneca Comparing IV Tracer Design with Oral/IV Crossover Clinical Design

Date Posted: November 24, 2011

Summary: A Resource and Data Quality Comparison: Absolute Bioavailability Data from an Oral / IV Crossover and an IV Isotropic Tracer Clinical Design. This poster, presented by AstraZeneca and Xceleron at the meeting of the American Association of Pharmaceutical Scientists (AAPS) in Washington DC in October 2011, describes the us of an IV microtracer studyContinue Reading

Read more >>